Skip to content
Brand AI

Andon Health

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2021

    “Demon stock” selectively discloses COVID test progress, receives regulatory letter; executives summoned

    Andon Health’s share price soared amid the COVID antigen testing hotspot; in December 2021 it disclosed FDA authorization progress early on Hudongyi and was questioned as “escorting” equity incentive exercises; in January 2022 it disclosed only partial Omicron test results, and a Shenzhen Stock Exchange regulatory letter said its Hudongyi replies had repeatedly been inaccurate and incomplete. Shenzhen Stock Exchange regulatory letter; Tianjin Securities Regulatory Bureau held regulatory talks with chairman Liu Yi and board secretary Wu Tong.

    Source